TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12087012

Group type: EXPERIMENTAL
Intervention: U.S. patients receiving conventional care
Number of subjects: 2849

Group type: COMPARATOR
Intervention: Canadian patients receiving conventional care
Number of subjects: 2849

Group type: EXPERIMENTAL
Intervention: U.S. patients before adjustment
Number of subjects: 2849

Group type: COMPARATOR
Intervention: Canadian patients before adjustment
Number of subjects: 2849

Group type: EXPERIMENTAL
Intervention: U.S. patients after adjustment for predictors
Number of subjects: 2849

Group type: COMPARATOR
Intervention: Canadian patients after adjustment for predictors
Number of subjects: 2849
Study: 11779598

Group type: EXPERIMENTAL
Intervention: Metformin therapy (850 mg, twice daily)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate induction (100 mg/day on cycle days 3‐7 of the second cycle) with Metformin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo therapy (twice daily)
Number of subjects: 56
Study: 9828903

Group type: EXPERIMENTAL
Intervention: Low dose testosterone treatment (100 mg subcutaneous implants every six months for at least two years, mean duration 3.3 ± 0.9 years)
Number of subjects: 22
Study: 8016878

Group type: EXPERIMENTAL
Intervention: OG 37‐325 (nva‐cyclosporine, cyclosporine G)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ERMBT (Erythromycin Breath Test)
Number of subjects: 20
Study: 2816609

Group type: EXPERIMENTAL
Intervention: HLBI monotherapy (3 million units daily for 4 days, then twice weekly)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combined HLBI with 5-FU (300 or 600 mg orally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Either HLBI treatment (monotherapy or combined)
Number of subjects: 24
Study: 776840

Group type: EXPERIMENTAL
Intervention: Cytoxan (CTX) alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combination chemotherapy (CTX, vincristine, and methotrexate - COM)
Number of subjects: 40
Study: 6102627

Group type: EXPERIMENTAL
Intervention: Clavulanic acid in combination with amoxycillin
Number of subjects: 0
Study: 30761459

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) application 1 month before surgery
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) application 2 weeks before surgery
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no MMC application)
Number of subjects: 65
Study: 29530884

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study: 30265463

Group type: EXPERIMENTAL
Intervention: Two-layered plasty using lightweight partially absorbable net (LPAN) Ultrapro (group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cruroraphy (group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 24888295

Group type: EXPERIMENTAL
Intervention: LOC eating in post‐pubertal youth
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: LOC eating in late‐puberty youth
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: LOC eating in pre‐pubertal youth
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes and palatable food consumption
Number of subjects: 468
Study: 22337760

Group type: EXPERIMENTAL
Intervention: MABP maintained between 60‐70 mmHg (MP group, n=50)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MABP <60 mmHg (LP group, n=36)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MABP >70 mmHg (HP group, n=36)
Number of subjects: 122

Group type: COMPARATOR
Intervention: All groups (MP, LP, HP)
Number of subjects: 122
Study: 20579167

Group type: EXPERIMENTAL
Intervention: Different types of stimuli (music, social stimuli, simulated social stimuli, individualized stimuli based on self-identity)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Live social stimuli
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Task and reading stimuli
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Music and self-identity stimuli
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Manipulative stimuli
Number of subjects: 111
Study: 17593865

Group type: EXPERIMENTAL
Intervention: HFA-BDP (200 microg once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BUD-TH (400 microg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FP-IH (250 microg twice daily)
Number of subjects: 40
Study: 15677301

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored nutrition intervention
Number of subjects: 782

Group type: COMPARATOR
Intervention: Generic nutrition information control group
Number of subjects: 782

Group type: COMPARATOR
Intervention: No-information control group
Number of subjects: 782
Study: 12374629

Group type: EXPERIMENTAL
Intervention: clomipramine+lithium (C+L)
Number of subjects: 10

Group type: COMPARATOR
Intervention: clomipramine+placebo (C+P)
Number of subjects: 10
Study: 10357419

Group type: EXPERIMENTAL
Intervention: 3D-CRT with a minimum tumor dose of 64.8 Gy to 81.0 Gy
Number of subjects: 743
Study: 8596484

Group type: EXPERIMENTAL
Intervention: Cephalic-phase insulin response (CPIR) before weight reduction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cephalic-phase insulin response (CPIR) after weight reduction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: First-phase insulin secretion during intravenous glucose tolerance test (IVGTT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of CPIR measurements before and after weight reduction
Number of subjects: 20
Study: 1763606

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6121965

Group type: EXPERIMENTAL
Intervention: Methyldopa treatment during pregnancy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Methyldopa treatment
Number of subjects: 195
Study: 30346340

Group type: EXPERIMENTAL
Intervention: Impression Cytology using EYEPRIM device with topical anesthesia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Impression Cytology using EYEPRIM device without topical anesthesia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Droplet digital PCR
Number of subjects: 46
Study: 30261237

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance
Number of subjects: 1448

Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance with successful procedures
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance with failed procedures
Number of subjects: 1448
Study: 26933886

Group type: EXPERIMENTAL
Intervention: AndoSan™ (n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 50
Study: 24945194

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg once daily for 3 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (matching oral placebo for 3 months)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg to 200 mg daily for 3 months, open-label follow-up)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (during open-label follow-up)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Thalidomide (open-label follow-up)
Number of subjects: 39
Study: 22677489

Group type: EXPERIMENTAL
Intervention: Contemporary understanding of MFH for management decisions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Literature review on MFH and undifferentiated pleomorphic sarcoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advances in the conception of MFH
Number of subjects: 0
Study: 21052881

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg before surgery and 150 mg every 8 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg before surgery and 550 mg every 12 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17107734

Group type: EXPERIMENTAL
Intervention: Interferon therapy (IFN-alpha)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 233
Study: 16274344

Group type: EXPERIMENTAL
Intervention: 18 sessions of comprehensive exercise-based outpatient cardiac rehabilitation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional care as provided by the treating doctor
Number of subjects: 113
Study: 12894011

Group type: EXPERIMENTAL
Intervention: Toupét partial fundoplication
Number of subjects: 95

Group type: COMPARATOR
Intervention: Watson partial fundoplication
Number of subjects: 95
Study: 10051804

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 7864427

Group type: EXPERIMENTAL
Intervention: 0.6 MAC desflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.6 MAC isoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no information supplied)
Number of subjects: 0
Study: 2288141

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid 500 mg once a day
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 46
Study: 6780210

Group type: EXPERIMENTAL
Intervention: spectinomycin
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: ampicillin-probenocid
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: thiamphenicol
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: minocyclin
Number of subjects: 420
Study: 31529104

Group type: EXPERIMENTAL
Intervention: Opioid therapy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nonopioid medication therapy
Number of subjects: 240
Study: 28893144

Group type: EXPERIMENTAL
Intervention: TCL reconstruction group (n=59)
Number of subjects: 117

Group type: COMPARATOR
Intervention: TCL release group (n=58)
Number of subjects: 117
Study: 26685082

Group type: EXPERIMENTAL
Intervention: Physician-nurse communication topics (family questions, family dynamics, spiritual/religious issues, cultural issues)
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Physician-family communication ratings (answering family's questions, listening to family, asking about treatments patient would want, helping family decide patient's treatment wishes, overall communication)
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Overall physician-family communication and helping family incorporate patient's wishes
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Nurses' concerns for patient or family
Number of subjects: 1173
Study: 23848231

Group type: EXPERIMENTAL
Intervention: Simvastatin plus black seed and garlic
Number of subjects: 300

Group type: COMPARATOR
Intervention: Simvastatin plus placebo
Number of subjects: 300
Study: 21828231

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 400 μg
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 600 μg
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 800 μg
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study: 20386129

Group type: EXPERIMENTAL
Intervention: Precompetition massage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional warm-up
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Precompetition massage combined with traditional warm-up
Number of subjects: 20

Group type: COMPARATOR
Intervention: Massage alone
Number of subjects: 20
Study: 18278078

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (income tertiles) in Australia
Number of subjects: 8733

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (income tertiles) in New Zealand
Number of subjects: 8733

Group type: COMPARATOR
Intervention: Socioeconomic status (income tertiles) in New Zealand vs Australia
Number of subjects: 8733

Group type: EXPERIMENTAL
Intervention: Obesity, smoking, and high white blood cell count at baseline
Number of subjects: 8733

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication, percutaneous coronary intervention, and coronary artery bypass surgery
Number of subjects: 8733
Study: 15776502

Group type: EXPERIMENTAL
Intervention: Fluconazole (test)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diflucan (reference)
Number of subjects: 26
Study: 11828038

Group type: EXPERIMENTAL
Intervention: Sahaja yoga intervention (2 hour session once a week for 4 months)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sahaja yoga intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control intervention (2 hour session once a week for 4 months)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 59
Study: 9933795

Group type: EXPERIMENTAL
Intervention: BTA stat test
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 240
Study: 7500601

Group type: EXPERIMENTAL
Intervention: VII/(81) scheme
Number of subjects: 74

Group type: COMPARATOR
Intervention: LSA2L2 scheme
Number of subjects: 74
Study: 2258635

Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha‐2b (rIFN alpha 2b) therapy for a total period of 20 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 68
Study: 6778264

Group type: EXPERIMENTAL
Intervention: Aluminum-precipitated grass extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycerosaline grass extract
Number of subjects: 0
Study: 31656057

Group type: EXPERIMENTAL
Intervention: ASSIST intervention (2 days of off-site training of influential students to encourage peers not to smoke during a 10-week period)
Number of subjects: 10730

Group type: EXPERIMENTAL
Intervention: ASSIST intervention
Number of subjects: 10730

Group type: COMPARATOR
Intervention: Control group (usual education)
Number of subjects: 10730
Study: 30955444

Group type: EXPERIMENTAL
Intervention: Scoring earlier in the OSCE
Number of subjects: 228

Group type: COMPARATOR
Intervention: Scoring later in the OSCE
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Presence of DRIFT (specifically primacy)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Overall influence of DRIFT on test outcomes
Number of subjects: 228
Study: 28408798

Group type: EXPERIMENTAL
Intervention: Low-dose SKA cytokines (IL-4, IL-10, anti-IL-1 antibodies at 10 fg/mL, orally administered at a dose of 20 drops/d for 12 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Disease-modifying antirheumatic drugs (DMARDs) therapy
Number of subjects: 39
Study: 25942722

Group type: EXPERIMENTAL
Intervention: NTCD-M3 (10^4 spores/d for 7 days)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NTCD-M3 (10^7 spores/d for 7 days)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NTCD-M3 (10^7 spores/d for 14 days)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NTCD-M3 (all doses combined)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NTCD-M3 (colonized patients)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NTCD-M3 (not colonized patients)
Number of subjects: 173
Study: 23645372

Group type: EXPERIMENTAL
Intervention: PR ortho-k
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (single-vision spectacles)
Number of subjects: 52
Study: 21748912

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control, low-fat meal
Number of subjects: 10
Study: 19127172

Group type: EXPERIMENTAL
Intervention: Combination treatment (fluoxetine + cognitive-behavioral therapy)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Overall (all active treatments)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Acute phase remitters
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Continuation phase remitters
Number of subjects: 439
Study: 17101261

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 14
Study: 15318251

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (4 ml/kg, 1.8 meq/kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 5% dextrose (Control)
Number of subjects: 55
Study: 11289198

Group type: EXPERIMENTAL
Intervention: Enhanced therapy for early syphilis
Number of subjects: 526

Group type: COMPARATOR
Intervention: Standard therapy for early syphilis
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Neurologic complaints
Number of subjects: 526
Study: 9260006

Group type: EXPERIMENTAL
Intervention: Multimodal pain treatment with intrathecal morphine, incisional bupivacaine and ibuprofen+acetaminophen po until hospital discharge (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy with iv PCA morphine weaned to acetaminophen+codeine po (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 40
Study: 7974091

Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation (VR) assistance through intensive outreach, case management, and enhanced work incentives.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 2481832

Group type: EXPERIMENTAL
Intervention: Esberitox N
Number of subjects: 70
Study: 30861167

Group type: EXPERIMENTAL
Intervention: Oral health education
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard care advice (Control)
Number of subjects: 111
Study: 26429609

Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution, 10%
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1655
Study: 23525631

Group type: EXPERIMENTAL
Intervention: Postoperative double-J stent (group 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Overnight-externalized ureteral catheter (group 2)
Number of subjects: 68
Study: 21933100

Group type: EXPERIMENTAL
Intervention: Omalizumab (OMA) added to optimized asthma therapy (OAT) for 32 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Optimized asthma therapy (OAT) alone for 32 weeks
Number of subjects: 82
Study: 18199474

Group type: EXPERIMENTAL
Intervention: Saliva cotinine concentration
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 66
Study: 16600583

Group type: EXPERIMENTAL
Intervention: 200mg niacin orally
Number of subjects: 47
Study: 14709924

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10766183

Group type: COMPARATOR
Intervention: GM‐CSF alone (2.5 microg/kg/day)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: GM‐CSF in combination with IL‐4 (0.5‐6.0 microg/kg/day)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Combination therapy (GM‐CSF and IL‐4)
Number of subjects: 1
Study: 8777364

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HES) 200/0.62
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 200/0.62
Number of subjects: 12
Study: 1864787

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (dextrose, 5 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise (60 W)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 6
Study: 6195021

Group type: EXPERIMENTAL
Intervention: 32% dextran 70
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 102
Study: 31854365

Group type: EXPERIMENTAL
Intervention: Supragingival control (Supra)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Supragingival control (Supra) plus scaling and root planing (SRP) on Day 0
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Supragingival control (Supra) on Day 0 and SRP 30 days later
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 25
Study: 29318859

Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao acupuncture combined with hyperbaric oxygen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hyperbaric oxygen only
Number of subjects: 40
Study: 26928753

Group type: EXPERIMENTAL
Intervention: MP-AzeFlu
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 24982456

Group type: EXPERIMENTAL
Intervention: Oxaliplatin and folinic acid-modulated fluorouracil (OFF)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Folinic acid and fluorouracil (FF)
Number of subjects: 168
Study: 22805286

Group type: EXPERIMENTAL
Intervention: Green tea polyphenols (GTP) 640 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19769480

Group type: EXPERIMENTAL
Intervention: Menoprogen (0.2 g extracts of five herbs per capsule, two capsules orally, twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menoprogen
Number of subjects: 0
Study: 17369516

Group type: EXPERIMENTAL
Intervention: Arm-focused training for 2 weeks
Number of subjects: 4
Study: 15345867

Group type: EXPERIMENTAL
Intervention: Fat-modified diet (SFA < 10%, MUFA 10-5%, PUFA up to 10%, cholesterol < 300 mg/day)
Number of subjects: 180
Study: 11393673

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9729372

Group type: EXPERIMENTAL
Intervention: Thyroxine therapy
Number of subjects: 3
Study: 9065130

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous promethazine
Number of subjects: 30